From the Discovery & Validation of Public Tumour-Specific Neoantigen Derived From the Dark Genome to a Clinical Trial in Uveal Melanoma: An Academic Perspective
Time: 2:45 pm
day: Day One
Details:
- How to test immunogenicity: in healthy donors, in patients or in preclinical models? What level of preclinical validation?
- Refining early phase testing: vaccine alone or in association with immunomodulators? Which one? Which schedule?
- Discussing primary objectives: CD4 and CD8 responses instead of clinical response. Which methods? How to monitor the Treg response?
